Mortality Profile of Tuberculosis Patients in Mandya District: A Cross-Sectional Study
DOI:
https://doi.org/10.56450/JEFI.2025.v3i03.006Keywords:
Tuberculosis, Mortality, NTEP, ComorbiditiesAbstract
Introduction: Tuberculosis (TB) remains a leading cause of mortality globally, especially among immunocompromised individuals such as those living with HIV. In 2022, TB accounted for 1.3 million deaths among HIV-negative individuals and 167,000 among PLHIV. Mortality in TB patients is influenced by factors like age, comorbidities (e.g., malignancy, liver and renal failure), and radiographic patterns. The COVID-19 pandemic significantly disrupted TB services, resulting in reduced case detection and a subsequent rise in TB deaths. Risk factors like sputum positivity, drug resistance, diabetes, and HIV were found to contribute to TB mortality. Objectives are to describe the mortality pattern of TB patients registered under NTEP in Mandya district (2018–2023) and to identify risk factors associated with TB mortality. Methodology: A facility-based cross-sectional study was conducted involving 168 TB death cases reported between Feb 2018 and Dec 2023. Data were collected via telephonic interviews with close relatives. Complete enumeration was used, and inclusion criteria focused on confirmed TB deaths under NTEP. Data were analyzed using descriptive and bivariate methods. Results: Most deaths occurred in males (76%) and individuals aged >60 years (39.2%). Pulmonary TB was present in 84% of cases, and 91.6% were on treatment. Respiratory insufficiency was the leading cause of death (79.6%). Deaths at home were more common (62%). COVID-19 years showed fewer deaths but with shorter diagnosis-to-death durations and longer hospital stays, suggesting pandemic-related service disruptions. Conclusion: TB mortality (2018–2023) in Mandya was higher among older, less literate males, with home deaths and COVID-19-related care disruptions highlighting the need for early detection and better healthcare access.
Downloads
References
1. Tobin, E.H. (2024) Tuberculosis overview, StatPearls [Internet]. [Accessed: 27 January 2025].Available at: https://www.ncbi.nlm.nih.gov/books/
2. Alisjahbana B, Sahiratmadja E, Nelwan EJ, Purwa AM, Ahmad Y, Ottenhoff TH, et al. The mortality of tuberculosis patients in Indonesia and its associated factors. BMC Infect Dis 2014;14-5
3. Centers for Disease Control and Prevention. TB and HIV Coinfection [Internet]. Atlanta: CDC; 2023 [cited 2024 Oct 27]. Available from: https://www.cdc.gov/tb/topic/basics/tbhivcoinfection.html
4. World Health Organization. Global Tuberculosis Report 2023 [Internet]. Geneva: WHO; 2023 [cited 2024 Oct 27]. Available from: https://www.who.int/news-room/fact-sheets/detail/tuberculosis
5. Kumar MS, Surendran D, Manu MS, Rakesh PS, Balakrishnan S. Mortality due to TB-COVID-19 coinfection in India. The International Journal of Tuberculosis and Lung Disease. 2021 Mar 1;25(3):250-1. https://doi.org/10.5588/ijtld.20.0947 DOI: https://doi.org/10.5588/ijtld.20.0947
6. Sridhar R, Viswanathan VK, Singh R, Keyzare R. Analysis of tuberculosis-related mortality during the first wave of the COVID pandemic at GHTM, tambaram sanatorium. Journal of Association of Pulmonologist of Tamil Nadu. 2021 May 1;4(2):65-8. https://doi.org/10.4103/japt.japt_41_21 DOI: https://doi.org/10.4103/japt.japt_41_21
7. Hazra D, Chawla K, Shenoy VP, Pandey AK, Nayana S. The aftermath of COVID-19 pandemic on the diagnosis of TB at a tertiary care hospital in India. Journal of Infection and Public Health. 2021 Aug 1;14(8):1095-8. https://doi.org/10.1016/j.jiph.2021.07.001 DOI: https://doi.org/10.1016/j.jiph.2021.07.001
8. Varshney K, Patel H, Kamal S (April 29, 2023) Trends in Tuberculosis Mortality Across India: Improvements Despite the COVID-19 Pandemic. Cureus 15(4): e38313. https://doi.org/10.7759/cureus.38313 DOI: https://doi.org/10.7759/cureus.38313
9. Sharma P, Khokhar A. Risk factors and perceptions about coronavirus disease among tuberculosis patients in Delhi, India: A cross-sectional study. Indian journal of tuberculosis. 2022 Oct 1;69(4):655-62. https://doi.org/10.1016/j.ijtb.2021.10.006 DOI: https://doi.org/10.1016/j.ijtb.2021.10.006
10. Krishnamoorthy Y, Ezhumalai K, Murali S, Rajaa S, Majella M, Sarkar S, et al. Development of prognostic scoring system for predicting 1-year mortality among pulmonary tuberculosis patients in South India. J Public Health. https://doi.org/10.1093/pubmed/fdac087 DOI: https://doi.org/10.1093/pubmed/fdac087
11. Straetemans M, Glaziou P, Bierrenbach A, Sismanidis C, Van Der Werf M. Assessing tuberculosis case fatality ratio: A meta-analysis. PLoS ONE. 2011;6. https://doi.org/10.1371/journal.pone.0020755 DOI: https://doi.org/10.1371/journal.pone.0020755
12. Alemu A, Bitew Z, Worku T, Gamtesa D, Alebel A. Predictors of mortality in patients with drug-resistant tuberculosis: A systematic review and meta-analysis. PLoS ONE. 2021;16. https://doi.org/10.1371/journal.pone.0253848 DOI: https://doi.org/10.1371/journal.pone.0253848
13. Taneja K, Mittal C, Saini S. Delays in the diagnosis and treatment of TB in India: A retrospective study. J Trop Med. 2022;2022:4532849.
14. Vashishtha R, Kumar P, Sharma SK. COVID-19 and tuberculosis: A study on the Indian healthcare crisis. J Clin Tuberc Other Mycobact Dis. 2021;23:100239.
15. Meneguim AC, Ferreira MD, et al. Impact of the COVID-19 pandemic on tuberculosis care in India: A systematic review. Int J Tuberc Lung Dis. 2021;25(8):784–91.
16. Pai M, Kasaeva T, Swaminathan S. Covid-19’s devastating effect on tuberculosis care – A path to recovery. N Engl J Med. 2022;386(16):1490–93. https://doi.org/10.1056/nejmp2118145 DOI: https://doi.org/10.1056/NEJMp2118145
17. Indian Council of Medical Research (ICMR). Decentralized care models and TB treatment strategies in India. Indian J Med Res. 2023;157(3):234–41.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Shashank Shetty, Almas Begum A (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- NonCommercial — You may not use the material for commercial purposes.
- NoDerivatives — If you remix, transform, or build upon the material, you may not distribute the modified material.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation.
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
